Exhibit 4.1
EXECUTION COPY
AMENDMENT NO. 1 TO THE AMENDED AND RESTATED
INVESTORS' AGREEMENT
AMENDMENT NO. 1 dated as of June 15, 2001 to the Amended and Restated
Investors' Agreement dated as of June 19, 2000, as amended (the "INVESTORS'
AGREEMENT").
W I T N E S S E T H:
WHEREAS, Charles River Laboratories International, Inc., a Delaware
corporation (the "COMPANY"), and several stockholders from time to time parties
thereto (the "STOCKHOLDERS") have entered into the Investors' Agreement;
WHEREAS, in order to change the notice provision to the Stockholders in
connection with their Registration Rights; and
WHEREAS, in order to permit other stockholders, not party to the
Investors' Agreement, to exercise their registration rights, the Company, DLJ
Merchant Banking II, Inc. and B&L CRL, Inc. desire to amend the Investors'
Agreement as provided hereunder in accordance with Section 6.06 thereof.
NOW, THEREFORE, it is agreed as follows:
SECTION 1. DEFINED TERMS; REFERENCES. Unless otherwise specifically
defined herein, each term used herein which is defined in the Investors'
Agreement has the meaning assigned to such term in the Investors' Agreement.
Each reference to "hereof," "hereunder," "herein" and "hereby" and each other
similar reference and each reference to "this Agreement" and each other similar
reference contained in the Investors' Agreement shall, after this Amendment
becomes effective, refer to the Investors' Agreement as amended hereby.
SECTION 2. AMENDMENT TO SECTION 5.01 OF THE INVESTORS' AGREEMENT.
(a) Section 5.01(a) is hereby amended by replacing "at least 30 days
prior to the anticipated filing" with "at least 2 days after the filing".
(b) Section 5.01(a)(ii) is hereby amended by replacing "within 15 days
after receipt" with "within 5 days after receipt", and by adding the phrase "and
any other stockholder (not party to this Agreement) entitled to registration
rights" after the parenthetical which defines "Holders" and after the term
"Holders".
(c) Section 5.01(b) is hereby amended by replacing "the 15-day period"
in the first sentence with "the 5-day period".
(d) Section 5.01(e) is hereby amended by adding the following paragraph
(E):
"(E) fifth: any securities proposed to be registered by any
other stockholders, not subject to this Agreement, that have
registration rights (allocated, if necessary for the offering not to
exceed the Maximum Offering Size, pro rata among such other
stockholders on the basis of the relative number of shares of
securities requested to be included in such registration)."
SECTION 3. AMENDMENT TO SECTION 5.02 OF THE INVESTORS' AGREEMENT.
(a) Section 5.02(a) of the Investors' Agreement is hereby amended by
replacing "at least 30 days prior to the anticipated filing" with "at least 2
days after the filing", by replacing "within 15 days after receipt" with
"within 5 days after receipt", and by adding the following sentence after the
definition of Incidental Rights:
"; PROVIDED that such Incidental Registration rights do not apply to a
registration pursuant to Section 6.4(b) of the Stock Purchase Agreement by and
among Charles River Laboratories, Inc., Primedica Corporation, TSI Corporation
and Genzyme Transgenics Corporations ("Genzyme"), dated February 6, 2001, as
amended from time to time ( the "Primedica Purchase Agreement")".
(b) Section 5.02(b)(ii) of the Investors' Agreement is hereby amended
and restated in its entirety to read as follows:
(ii) second, all Registrable Securities requested to
be included in such registration by the DLJMB Entities and
their Permitted Transferees, or any Other Stockholder pursuant
to this Section 5.02 and any other stockholder entitled to
registration rights requested to be included (allocated if
necessary for the offering not to exceed the Maximum Offering
Size, pro rata among such Stockholders and any other
stockholders, not party to this Agreement, on the basis of the
relative number of shares of Registrable Securities so
requested to be included in such registration); PROVIDED that
the Company may permit Genzyme to sell more than its pro rata
amount up to 658,945 shares of the Company's common stock
which Genzyme received pursuant to the Primedica Purchase
Agreement.
2
SECTION 4. GOVERNING LAW. THIS AMENDMENT SHALL BE GOVERNED BY AND
CONSTRUED IN ACCORDANCE WITH THE LAWS OF THE STATE OF DELAWARE WITHOUT REGARD TO
THE CONFLICTS OF LAW RULES OF SUCH STATE.
SECTION 5. EFFECTIVENESS. This Amendment will be effective as of the
date hereof when signed by the Company, DLJ Merchant Banking II, Inc. and B&L
CRL, Inc.
3
IN WITNESS WHEREOF, the undersigned have executed this Amendment as of
the 15th day of June 2001.
Charles River Laboratories,
International, Inc.
By:
------------------------
Name:
Title:
DLJ Merchant Banking II, Inc.
By:
------------------------
Name:
Title:
B&L CRL, Inc.
By:
------------------------
Name:
Title:
4